RecruitingNCT06295965

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)

Sponsor

University of Washington

Enrollment

2,000 participants

Start Date

Jan 2, 2024

Study Type

OBSERVATIONAL

Conditions

Ovarian Carcinoma Recurrent Ovarian Carcinoma Recurrent Malignant Solid Neoplasm Recurrent Fallopian Tube Carcinoma Recurrent Primary Peritoneal Carcinoma Clonal Cytopenia of Undetermined Significance Clonal Hematopoiesis Idiopathic Cytopenia of Undetermined Significance Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder Myeloid Neoplasm Post Cytotoxic Therapy

Summary

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.

Eligibility

Inclusion Criteria6

Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:
Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy
OR
Subjects who have or have had a solid tumor diagnosis and any of the following:
At least 4 months of exposure to a PARP inhibitor
Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm